Search Results - "Ferrarotto, R."

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Lim, B., Ueno, N.T., Litton, J.K., Ferrarotto, R., Chang, J.T., Moulder, S.L., Lin, S.-Y.

“…High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to the potential…”
Get full text

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors by Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J.V., Kapoun, A.M., Xu, L., Munster, P.

“…Brontictuzumab is a monoclonal antibody that targets Notch1 and inhibits pathway activation. The purpose of this first-in-human study was to determine the…”
Get full text

Association between KRAS mutation and lung metastasis in advanced colorectal cancer by Pereira, A A L, Rego, J F M, Morris, V, Overman, M J, Eng, C, Garrett, C R, Boutin, A T, Ferrarotto, R, Lee, M, Jiang, Z-Q, Hoff, P M, Vauthey, J-N, Vilar, E, Maru, D, Kopetz, S

“…Background: KRAS mutations have been associated with lung metastases at diagnosis of metastatic colorectal cancer (mCRC), but the impact of this mutation on…”
Get full text

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Ueno, N.T., Ferrarotto, R., Chang, J.T., Lin, S.-Y.

Get full text

Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study by de Sousa, L. Guimaraes, Liu, S., Bhosale, P., Altan, M., Darbonne, W., Schulze, K., Dervin, S., Yun, C., Mahvash, A., Verma, A., Futreal, A., Gite, S., Cuentas, E. Parra, Cho, W.C., Wistuba, I., Yao, J.C., Woodman, S.E., Halperin, D.M., Ferrarotto, R.

“…•In this phase II trial of atezolizumab and bevacizumab in advanced MCC patients, the ORR was 64 %, with 27 % complete responses.•Atezolizumab and bevacizumab…”
Get full text

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al by McGrail, D.J., Pilié, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Ueno, N.T., Ferrarotto, R., Chang, J.T., Lin, S.-Y.

Get full text

Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting by Sandulache, V.C., Lei, Y.L., Heasley, L.E., Chang, M., Amos, C.I., Sturgis, E.M., Graboyes, E., Chiao, E.Y., Rogus-Pulia, N., Lewis, J., Madabhushi, A., Frederick, M.J., Sabichi, A., Ittmann, M., Yarbrough, W.G., Chung, C.H., Ferrarotto, R., Mai, Weiyuan, Skinner, H.D., Duvvuri, U., Gerngross, P., Sikora, A.G.

Get full text

G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy by Roberts, P, He, S, Schvartsman, G, Patil, T, Sorrentio, J, Bisi, J, Hoyer, R, Schuster, S, Strum, J, Heymach, J, Ferrarotto, R, Sharpless, N, Shapiro, G, Malik, R

“…Background: Many patients present with pretreatment lymphopenia or develop lymphopenia as a consequence of chemotherapy (chemo). Cytotoxic treatments can cause…”
Get full text

Identification of Anatomic Correlates of Failure in Patients With T4a Larynx Cancer by Mohamed, A.S.R, Pham, B.H, Messer, J.A, Morrison, W.H, Zafereo, M, Hessel, A.C, Lai, S, Kies, M.S, Ferrarotto, R, Garden, A.S, Weber, R.S, Rosenthal, D.I, Fuller, C.D

Get full text

Outcomes of Head and Neck Adenoid Cystic Carcinoma Treated Definitively With Surgery and Postoperative Intensity Modulated Radiation Therapy by Gottumukkala, S, Garden, A.S, Frank, S.J, Fuller, C.D, Gunn, G.B, Morrison, W.H, Phan, J, Rosenthal, D.I, Skinner, H.D, El-Naggar, A.K, Ferrarotto, R, Kupferman, M.E, Beadle, B.M

Get full text

EP-1068: Impact of pretreatment primary tumor volume on survival of patient with T4a larynx cancer by Mohamed, A, Shiao, J, Messer, J, Morrison, W, Zafereo, M, Hessel, A, Lai, S, Kies, M, Ferrarotto, R, Garden, A, Weber, R, Rosenthal, D, Fuller, C.D

Get full text

6598 POSTER Combination of Capecitabine and Oxaliplatin (CAPOX) is an Effective Option for the Treatment of Neuroendocrine Tumours (NET) by Ferrarotto, R, Testa, L, Riechelmann, R.R, Saad, M, Siqueira, L.T, Costa, F.P, Hoff, P.M

Get full text

Efficacy and Tolerability of Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFRi) for Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC): a Systematic Review and Meta-Analysis by Hoff, C.O., Manzi, J., Neto, F. Lazar, Ferrarotto, R.

“…ACC has a high rate of recurrence and distant metastasis. There is no FDA-approved systemic therapy for R/M ACC. Given high VEGFA expression in ACC and…”
Get full text

907P Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II by Locati, L.D., De Cecco, L., Bonini, F., Orlandi, E., Sottotetti, F., Licitra, L.F.L., Ferrarotto, R.

Get full text

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma by Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G., Rischin, Danny

“…A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients…”
Get full text

Survival Outcomes following Pulmonary Metastasis-Directed Local Therapy (PM-LT) Relative to No Metastasis-Directed Intervention in Adenoid Cystic Carcinoma (ACC) by Hoff, C.O., Feng, L., Bonini, F., Sousa, L.G., Wang, K., Siqueira, J.M., Purushothaman, A., Nguyen, Q.N., El-Naggar, A.K., Mehran, R., Ferrarotto, R.

“…ACC has a high rate of recurrence and distant metastasis (DM), despite aggressive curative-intent primary therapy. The lung is the most common site of DM, most…”
Get full text

909P TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype by Mota Siqueira, J., Mitani, Y., Marques-Piubelli, M.L., Hoff, C.O., Bonini, F., Purushothaman, A., McGrail, D., El-Naggar, A., Ferrarotto, R.

Get full text

908P Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) by Hoff, C.O., de Sousa, L.G., Bonini, F., Dal Lago, E., Wang, K., Mota Siqueira, J., Cortez, M.A., Mitani, Y., Purushothaman, A., El-Naggar, A., Ferrarotto, R.

Get full text

A Lymph Node Immune Score (LNIS) Identifies Prognostic Immune Phenotypes Shared across Head and Neck Cancers by Karpinets, T., Garden, A.S., Rosenthal, D.I., Fuller, C.D., Frank, S.J., Gunn, G.B., Phan, J., Morrison, W.H., Lee, A., Moreno, A.C., Song, X., Mitani, Y., Ferrarotto, R., Gross, N.D., Zhang, J., Myers, J.N., El-Naggar, A.K., Spiotto, M.T.

“…Lymph node metastases (LNMs) reflect the interplay between cancer cells and immune cells in the lymph node microenvironment. Given that the immune…”
Get full text

Multicenter Phase III Trial of Chemoradiation (CRT) with IMPT vs. IMRT for Oropharyngeal Squamous Cell Carcinoma (OPSCC): Secondary Analysis of Association of Lymphopenia with Treatment Modality, Emergency Room (ER) Visits and Hospital Admission (HA) by Grippin, A., Foote, R.L., Busse, P.M., Rosenthal, D.I., Hernandez, M., Garden, A.S., Sturgis, E.M., Ferrarotto, R., Gunn, G.B., Patel, S.H., Lee, N.Y., Lin, A., Snider, J.W., McDonald, M.W., Henson, C., Bajaj, G.K., Kalman, N.S., Parvathaneni, U., Frank, S.J.

“…Radiation induced lymphopenia (RIL) is common, but its clinical implications are not well defined. In this secondary analysis of a phase III randomized…”
Get full text